Estradiol

Additional information:
Estradiol is an Estrogen. Estradiol is the 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.The mechanism of action of estradiol is as an Estrogen Receptor Agonist. Therapeutic Estradiol is a steroid sex hormone vital to the maintenance of fertility and secondary sexual characteristics in females. Typically esterified, estradiol derivatives are formulated for oral or parenteral administration.|Product information|CAS Number: 50-28-2|Molecular Weight: 272.38|Formula: C18H24O2|Synonym:|Beta-Estradiol|17beta-Estradiol|Oestradiol|Estrace|Dihydrofolliculin|β-Estradiol|Estradiol|17β-Oestradiol|Chemical Name: (8R, 9S, 13S, 14S, 17S)-13-methyl-6, 7, 8, 9, 11, 12, 14, 15, 16, 17-decahydrocyclopenta[a]phenanthrene-3, 17-diol|Smiles: C[C@]12CC[C@H]3[C@@H](CCC4=CC(O)=CC=C43)[C@@H]1CC[C@@H]2O|InChiKey: VOXZDWNPVJITMN-ZBRFXRBCSA-N|InChi: InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO: 54 mg/mL(198.{{GLP-1 receptor agonist 2} MedChemExpress|{GLP-1 receptor agonist 2} GCGR|{GLP-1 receptor agonist 2} Purity & Documentation|{GLP-1 receptor agonist 2} References|{GLP-1 receptor agonist 2} manufacturer|{GLP-1 receptor agonist 2} Epigenetics} 25 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Estradiol induces new dendritic spines and synapses on hippocampal CA1 pyramidal cells. Estradiol treatment resulted in a 46% increase in NMDA receptor binding.PMID:25429455 Estradiol treatment increases NMDA receptor binding in parallel with dendritic spine and synapse density. Estradiol treatment results in increased sensitivity of CA1 pyramidal cells to NMDA receptor-mediated synaptic input and that this increase is well correlated with the estradiol-induced increase in dendritic spine density in the apical dendritic tree of these cells. 17 beta-estradiol is found to reduce Ba2+ entry reversibly via Ca2+ channels in acutely dissociated and cultured neostriatal neurons. 17 alpha-Estradiol also reduces Ba2+ currents but is significantly less effective than 17 beta-estradiol in rat neostriatal neurons. 17 beta-estradiol exerts a dose-dependent inhibition of IL-1-, TNF-, and IL-1 and TNF-induced production of bioassayable IL-6. Estradiol inhibits both TNF-induced IL-6 production and osteoclast development in primary bone cell cultures derived from neonatal murine calvaria.|In Vivo:|Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. Estradiol alone can reverse the ovariectomy-induced decrease in spine density. Estradiol combined with Progesterone initially increases spine density for a period of 2 to 6 hours but then results in a much sharper decrease than is observed following estradiol alone.|References:|Girasole G, et al. J Clin Invest, 1992, 89(3), 883-891.Mermelstein PG, et al. J Neurosci, 1996, 16(2), 595-604.Woolley CS, et al. J Neurosci, 1997, 17(5), 1848-1859.Products are for research use only. Not for human use.|